US District Judge Daniel Crabtree ruled numerous lawsuits against the marketer and manufacturer of EpiPen may proceed as a nationwide class-action under a federal racketeering statute.
State prosecutors describe a price fixing scheme involving more than a dozen companies and as many executives responsible for sales, marketing, and pricing.